The medical device outsourcing market was valued at USD 157.8 billion in 2025 and is projected to reach USD 421.9 billion by 2033, growing at a CAGR of 13.4% from 2026 to 2033. Asia Pacific leads with a 41.5% share, and contract manufacturing is the largest service line. The sections below cover market size, growth drivers, segment leaders, and the companies shaping the industry.

How Big Is the Medical Device Outsourcing Market?

The medical device outsourcing market is estimated at USD 175.4 billion for 2026, which is roughly 11% above the 2025 base. Growth then compounds at 13.4% annually, so the 2033 forecast of USD 421.9 billion is about 2.4 times the 2026 estimate. These two ratios are our own arithmetic on the published figures, not additional data points.

Regionally, Asia Pacific captured 41.5% of global revenue in 2025. China held the largest share within the region, helped by manufacturing infrastructure, supportive government initiatives, and cost-competitive contract manufacturers. In the broader view, North America is projected to grow considerably through 2033. The U.S. held the largest revenue share in 2025 as device makers there hand over regulatory work, product design, and maintenance to specialists. Europe is expected to expand at a CAGR of 13.2%, led by Germany and the UK.

The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.

Why Are Device Makers Outsourcing? Key Market Drivers

Pricing pressure is the starting point. Demand for medical devices keeps rising, but price competition keeps squeezing margins, so manufacturers must cut costs without weakening R&D, speed to market, safety, or quality. Outsourcing converts fixed costs into flexible ones. Smaller firms in particular often lack the skilled labor and technical resources to finish projects in-house.

Regulation is the second driver, and it works differently from cost. Approval procedures are becoming stricter and slower, and companies increasingly want clearance on the first attempt. Rules also change across business activities and geographies, and non-compliance can mean penalties, delays, and lost revenue. Geographic expansion adds to the load. Companies chasing faster approvals in new markets lean on outsourced regulatory affairs expertise instead of building that capability in every region.

R&D economics and demographics round out the picture. In North America, high R&D costs push companies toward third-party vendors with deep domain expertise. In Asia Pacific, a rapidly aging population in countries like China and India raises demand for affordable devices.

The most interesting driver is strategic rather than financial. By outsourcing selected operations, OEMs gain agility, lower operating costs, shorter time to market, and better returns, which lets them reposition themselves from cost centers into strategic investments.

Download a free sample report or claim your copy of this full market intelligence report

Which Segments Lead the Medical Device Outsourcing Market?

By service. Contract manufacturing accounted for 53.6% of 2025 revenue, the largest share. Asia Pacific is considered the hub for contract manufacturing of devices. Quality assurance is expected to grow at the fastest CAGR through the forecast period. The reason is a stronger emphasis on regulatory compliance, more complex product development, and a rising need to keep safety and efficacy high. Pharmaceutical, biotechnology, and device companies are all passing quality assurance work to specialist providers. The pattern suggests that outsourcing began as a way to buy production capacity and is now increasingly a way to buy confidence in compliance.

By application. Cardiology held the largest share in 2025, supported by growing demand for cardiac devices and the rising prevalence of cardiovascular conditions such as myocardial infarction, atrial fibrillation, and congenital heart disease. General and plastic surgery is projected to grow fastest because rising cosmetic surgery demand drives outsourcing of surgical devices. Fixation devices, extremity splints, and epilators require specialized molding and machining and are typically outsourced to component manufacturers.

By class. Class II devices held the largest revenue share in 2025. Nearly 43% of medical devices fall into this class, which includes catheters, syringes, surgical gloves, blood pressure cuffs, pregnancy test kits, contact lenses, and blood transfusion kits. Class I devices make up about 47% of devices and are expected to grow at a considerable CAGR. They are noninvasive, and 95% of them are exempt from regulatory procedures because of their low risk. Most are also exempt from FDA 510(k) and PMA requirements, which makes them the fastest to bring to market. Class I leads by volume of devices while Class II leads by revenue, so the biggest opportunity sits where regulatory complexity and demand overlap.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Who Are the Prominent Players in the Medical Device Outsourcing Market?

The competitive field blends testing laboratories, clinical research organizations, regulatory consultancies, and manufacturing specialists. Fourteen companies are profiled in the report: SGS SA, Laboratory Corporation of America Holdings, Eurofins Scientific, Pace Analytical Services, Intertek Group plc, WuXi AppTec, Charles River Laboratories, Freyr, PAREXEL International Corporation, Criterium, Medpace, ICON plc, IQVIA Inc., and Integer Holdings Corporation. These companies collectively hold the largest market share and influence industry direction. Their strategies center on mergers, partnerships, acquisitions, and technological innovation.

Recent deals show how that plays out. In January 2026, Labcorp completed the sale of its early development medical device testing business to NAMSA, strengthening NAMSA’s testing and development capabilities while reshaping Labcorp’s outsourced device services portfolio. In January 2025, Integer acquired Precision Coating, expanding its manufacturing capabilities in coating, surface treatment, and laser processing. In August 2025, IQVIA announced a strategic collaboration with Flagship Pioneering to accelerate life science company development. Taken together, these moves point to specialization: companies are buying focused technical capabilities rather than broad capacity.

Explore the full list of profiled companies operating in this market with recent strategic initiatives